|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest bearing demand deposits with banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Cash and Cash Equivalents | ||||||||||||||||||||
| Securities available for sale | ||||||||||||||||||||
| Restricted investment in bank stock | ||||||||||||||||||||
| Loans receivable, net of allowance for credit losses of $12,499 in 2023; $12,449 in 2022 | ||||||||||||||||||||
| Loans receivable, net of allowance for credit losses of $12,456 in 2026; $12,039 in 2025 | ||||||||||||||||||||
| Paycheck Protection Program loans receivable | ||||||||||||||||||||
| Premises and equipment, net of accumulated depreciation | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest bearing | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Total Deposits | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Common stock, $1 par value; authorized 20,000,000 shares; 2026 issued 7,840,882 shares; outstanding 7,405,604 shares; 2025 issued 7,822,622 shares; outstanding 7,547,344 shares | ||||||||||||||||||||
| Surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost: 435,278 and 275,278 shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...
